8 August 2017 - NICE recommends Erbitux in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic head and neck cancer in the oral cavity.

Merck announced today that the NICE for England has issued a positive Final Appraisal Determination recommending the routine National Health Service use of Erbitux (cetuximab) in combination with platinum-based chemotherapy as a first-line therapy for the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) in the oral cavity 

NICE’s decision confirms the positive benefit Erbitux can have on the survival of patients in this setting. Erbitux is already established and reimbursed as an effective therapy for different stages of SCCHN across many countries worldwide.

Read Merck KGaA press release